$BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC)$'s rise in the biotech industry is truly remarkable!
It's projected that by 2025, the company will achieve positive GAAP operating profit, marking a milestone event that will elevate its standing in the industry. What's even more impressive is that BeiGene's market cap has surpassed that of Heng Rui Medicine for the first time, showcasing its growing market dominance.
Its core product, Bruton’s tyrosine kinase (BTK) inhibitor Zanubrutinib, has seen strong performance, with sales reaching 12.9 billion RMB in the first three quarters of 2024, a 91% year-on-year growth.
Additionally, the approval of Tislelizumab for gastric cancer in the U.S. has helped push its overseas revenue above 50%. With such strong fundamentals, BeiGene's future looks incredibly promising!
Comments